Skip to main content

All Articles

Fertility Preservation and Benefits of OFS
Polly Niravath, MD, discusses fertility preservation in premenopausal women with breast cancer who are undergoing ovarian function suppression (OFS) treatment. Read More ›

Setting Patient Expectations of OFS Treatment
Listen as a nurse navigator discusses ovarian function suppression (OFS) and the subsequent impact of OFS on premenopausal women with breast cancer. Read More ›

Breast cancer treatments pose significant fertility risks, emphasizing the importance of fertility counseling and preservation techniques, as highlighted by a study on young breast cancer patients. Read More ›

Adding aromatase inhibitors to ovarian function suppression significantly improves invasive disease-free survival and underscores the importance of individualized treatment decisions based on clinicopathological factors. Read More ›



Recognizing the complexities of treatment with oral medications is an important step toward successful outcomes. Read More ›

The FDA recently announced the publication of an article reviewing 50 years of the FDA’s experience with clinical research related to the use of cannabis in drug development. Read More ›

The addition of pembrolizumab to standard-of-care FLOT (docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil) prolongs pathologic complete response (pCR) and event-free survival (EFS) in patients with resectable gastric and gastroesophageal junction (G/GEJ) adenocarcinoma. Read More ›

The addition of durvalumab and bevacizumab to transarterial chemoembolization (TACE) significantly improved progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC) eligible for embolization. Read More ›

Page 28 of 299